Anthology Diagnostics offers advanced cancer genomic testing using next-generation sequencing (NGS) and biomarker analysis. We provide oncologists with clinically actionable molecular data for personalized treatment decisions in solid tumors and hematologic malignancies.
Funding
Funding not disclosed
Founders
Product
Problem
Oncologists require precise molecular data to guide personalized cancer treatment decisions, but traditional genomic testing can be time-consuming and may require substantial tissue samples. This can lead to delays in initiating therapy and potentially limit treatment options for patients with limited tissue availability.
Solution
Anthology Diagnostics provides advanced cancer genomic testing services, leveraging next-generation sequencing (NGS) and biomarker analysis to deliver clinically actionable molecular data. Our platform supports oncologists in identifying therapeutic targets and stratifying patient risk for both solid tumors and hematologic malignancies. We offer efficient turnaround times and clear reporting, facilitating informed and timely treatment decisions. As part of the Genomic Testing Cooperative network, we contribute to advancing genomic insights through data sharing and AI modeling.
Target Audience
Our primary customers are oncologists, pathologists, and laboratory directors seeking comprehensive genomic profiling to inform personalized cancer treatment strategies.
Features
- Next-generation sequencing (NGS) and biomarker testing for solid tumors, hematologic malignancies, and liquid biopsies.
- DNA and RNA-based profiling to identify mutations, fusions, copy number variations (CNVs), tumor mutational burden (TMB), and microsatellite instability (MSI) status.
- Comprehensive panels for common solid tumors (e.g., lung, colorectal, breast, prostate) and hematologic malignancies (e.g., leukemia, lymphoma, multiple myeloma).
- Liquid biopsy options for non-invasive monitoring and when tissue samples are limited.
- Clinically actionable reports that highlight FDA-approved therapies, relevant clinical trials, and NCCN-guided treatment options.
- Reduced sample size requirements and efficient turnaround times to minimize treatment initiation delays.
- Secure provider portal for report delivery with support for HL7 and PDF format integration into Electronic Health Records (EHRs).
- Collaboration with molecular pathology experts for consultation on test selection, sample handling, and result interpretation.